Abcam, ab255733, Anti-HIF Prolyl Hydroxylases antibody [EPR3664(2)-25]

Size: 100µL / 1mL
Rabbit Recombinant Monoclonal HIF Prolyl Hydroxylases antibody. Suitable for IHC-P, IP, WB, Flow Cyt (Intra) and reacts with Human samples. Cited in 1 publication.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR3664(2)-25,
Isotype:IgG,
Carrier free:No,
Reacts with:Human,
Applications:IHC-P, WB, IP, Flow Cyt (Intra)See reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
HIF prolyl hydroxylases also known as EglN or prolyl hydroxylase domain proteins (PHDs) are enzymes that modulate the stability of hypoxia-inducible factors (HIFs). These enzymes primarily facilitate the hydroxylation of prolyl residues on HIF-α subunits which marks them for degradation via the ubiquitin-proteasome pathway. Mammals express three isoforms: PHD1 PHD2 and PHD3 with PHD2 being the most widely studied. PHDs are expressed ubiquitously with higher levels observed in the liver kidneys and lung. The molecular mass of these enzymes is typically around 40 kDa.
Biological function summary
HIF prolyl hydroxylases play an essential role in oxygen sensing and homeostasis by regulating the activity of HIF-α subunits. Under normoxic conditions the hydroxylation of HIF-α by these hydroxylases permits recognition by the von Hippel-Lindau (VHL) protein leading to proteasomal degradation. In hypoxic conditions the decreased activity of HIF prolyl hydroxylases allows HIF-α stabilization and heterodimerization with HIF-β facilitating transcription of target genes involved in angiogenesis and metabolism. PHD2 is predominantly responsible for targeting HIF-1α.
Pathways
HIF prolyl hydroxylases integrate into the hypoxia response pathway. Oxygen-dependent regulation of HIF by these hydroxylases affects processes such as angiogenesis and erythropoiesis through interaction with several proteins including endothelial growth factor (VEGF) and erythropoietin (EPO). Beyond the hypoxia pathway they participate in metabolic pathways influencing cellular energy homeostasis thereby impacting proteins involved in metabolic regulation.
HIF prolyl hydroxylases associate with cancer and ischemic diseases. Dysregulation of these hydroxylases can lead to excessive stabilization of HIF-α which promotes tumor growth and metastasis due to enhanced angiogenesis and altered metabolism associated with cancer cells. In ischemic conditions reduced prolyl hydroxylases activity can offer protection by inducing adaptive responses through HIF-α stabilization. Their connectivity to the VHL protein further links them to von Hippel-Lindau disease characterized by tumor development in multiple organs.